Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate

Trial Profile

Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Contusugene ladenovec (Primary) ; Methotrexate
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Introgen Therapeutics
  • Most Recent Events

    • 23 Jul 2008 Further analysis of results from the pivotal phase III trial presented at AACR 2008. These results are included in the BLA application to the US FDA and the MAA to the EMEA.
    • 17 Jul 2008 Results of a prespecified subgroup analysis of the p53 biomarker population to be presented at the AACRCentennial Conference on Translational Cancer Medicine 2008
    • 29 May 2008 Results presented at ASGT 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top